Myriad Genetics
Open
$4.76
Prev. Close
$4.77
High
$4.76
Low
$4.73
Market Snapshot
$436.24M
-1.2
-1.41
$837.6M
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. The company is headquartered in Salt Lake City, Utah and currently employs 2,700 full-time employees. The firm develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The firm is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. The company also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
emptyResult
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. The company is headquartered in Salt Lake City, Utah and currently employs 2,700 full-time employees. The firm develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The firm is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. The company also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
Recently from Cashu
Myriad Genetics Advances in Genetic Testing Enhance Personalized Medicine and Cancer Care
Innovative Advances in Genetic Testing Propel Myriad Genetics Forward Myriad Genetics, a leader in the field of molecular diagnostics and personalized medicine, continues to make significant strides i…
Myriad Genetics Advances Precision Medicine with Expanded Genetic Testing Services
Myriad Genetics Expands Genetic Testing Offerings in Precision Medicine Myriad Genetics is making significant strides in the field of precision medicine, demonstrating its commitment to evolving and e…
Myriad Genetics Quarterly Preview: Test Volumes, Payer Mix and Financial Outlook
NEW YORK, Feb 23 (Reuters) - Myriad Genetics is scheduled to report quarterly results on Monday, and the company's diagnostic operations take center stage as management prepares to detail recent trend…
Stock Update: Myriad Genetics Performance and Market Trends
Sure! Please provide the text you'd like me to summarize into a 300-word paragraph.